Skip to main content
PharmaTher Holdings Ltd. logo

PharmaTher Holdings Ltd. — Investor Relations & Filings

Ticker · PHRM ISIN · CA71716H1082 LEI · 529900PIPSZ1ZSWF3A21 CSE Manufacturing
Open in API
Filings indexed 279 across all filing types
Latest filing 2023-01-27 Regulatory Filings
Country CA Canada
Listing CSE PHRM

About PharmaTher Holdings Ltd.

https://www.pharmather.com/

PharmaTher Holdings Ltd. is a specialty pharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics, primarily focusing on ketamine and psychedelic compounds. The company's strategy involves advancing three core assets: the KETARX™ portfolio of ketamine drugs, which targets neuropsychiatric and pain disorders; the proprietary PharmaPatch™ microneedle patch platform, designed for the transdermal delivery of ketamine, psychedelics, and GLP-1 drugs; and a 49% ownership interest in Sairiyo Therapeutics Inc., which is developing a patented oral formulation of cepharanthine for infectious diseases and cancer. PharmaTher is focused on achieving regulatory approval for its pipeline candidates to address significant global unmet medical needs in mental health, neurological, and pain disorders.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2023-01-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PharmaTher Holdings has submitted an application to the FDA for Orphan Drug Designation for ketamine to treat Rett Syndrome. It discusses the regulatory process, the potential benefits of the designation, and background on the drug and disease. There are no financial statements, earnings data, or detailed financial analysis. The document is an announcement of a regulatory submission and related business development, not a financial report or detailed investor presentation. It is not a report publication announcement since it contains substantive information about the regulatory filing and business implications. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-01-18 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release from PharmaTher Holdings providing an update on the development programs and expected milestones for their drug KETARX™ in 2023. It discusses clinical development progress, regulatory pathways (ANDA and 505(b)(2)), FDA orphan drug designations, and anticipated FDA approvals. The content is forward-looking and strategic, focusing on development updates and regulatory plans rather than presenting actual financial data or detailed financial results. It is not a full financial report, earnings release, or regulatory filing. The document is an update announcement about development programs and milestones, which fits best under Capital/Financing Update (CAP) as it relates to company progress and potential commercialization impacting capital and financing outlook. It is not a report publication announcement or regulatory filing, as it contains substantive company program updates rather than just announcing a report release or certification. Therefore, the most appropriate classification is CAP with high confidence.
2023-01-11 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that PharmaTher Holdings Ltd. has received FDA orphan drug designation for ketamine for a new indication. It discusses the orphan drug status, the benefits of such designation, and provides background on the company and the drug. There are no financial statements, no detailed financial performance data, no regulatory certifications, no voting results, no management or board changes, no earnings data, and no detailed investor presentation content. The document is a corporate announcement about a regulatory milestone related to drug designation. It is not a report, transcript, or financial filing. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-12-15 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing a poster presentation of clinical study results related to ketamine treatment for Parkinson's disease. It discusses Phase 1/2 clinical study data, safety, efficacy, and plans to engage the FDA for a Phase 3 study under the 505(b)(2) regulatory pathway. The document is not a full financial report, earnings release, or regulatory filing. It is a detailed announcement of clinical trial results and future plans, typical of a corporate press release or investor update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is not a presentation document per se, but an announcement of clinical data presentation at a scientific conference. Given the nature of the content and the absence of financial statements or regulatory compliance documents, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2022-11-14 English
Form of proxy - English.pdf
AGM Information Classification · 100% confidence The document is a Form of Proxy for an Annual General Meeting (AGM) of PharmaTher Holdings Ltd. It includes details about the meeting date, proxy appointment, voting instructions, and resolutions to be approved such as election of directors and appointment of auditor. There is no financial data or report content, only proxy solicitation and voting instructions related to the AGM. This matches the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM. The document length is about 4964 characters, and it is not a report publication announcement or certification. Therefore, the correct classification is AGM Information (AGM-R).
2022-11-02 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.